This policy identifies which noninvasive tests for hepatic fibrosis Aetna considers medically necessary, which are experimental/investigational (not covered), and important constraints and limitations that affect appropriate use and claims documentation. The policy lists covered modalities including transient elastography (e.g., FibroScan), FibroTest‑ActiTest/HCV‑FibroSure, magnetic resonance elastography (MRE) for certain NASH indications, and the Enhanced Liver Fibrosis (ELF) test, and it also specifies multiple procedures and biomarkers considered investigational (for example, ARFI, quantitative mpMRI/LiverMultiScan, serum ferritin, and various miRNA assays).
When tests are used clinically, claims should match the listed CPT/HCPCS and ICD‑10 coding and be supported by documentation of the clinical indication and numeric test results where applicable (for example, FibroTest score, ELF index, or median liver stiffness in kPa). The policy identifies numerous CPT and ICD‑10 codes that are not covered for investigational indications (for example, quantitative MRI CPT codes 0648T–0724T and ferritin CPT code 82728) and notes that artificial intelligence approaches currently have no specific billing code and are considered investigational for fibrosis/NAFLD applications.
The coverage stance emphasizes that noninvasive tests have the greatest validated utility for identifying advanced fibrosis or cirrhosis rather than for distinguishing early or intermediate stages. Guideline and systematic‑review evidence cited in the policy indicate that serum marker panels and imaging techniques can reduce the need for biopsy in some patients but none fully supplants liver biopsy across all clinical scenarios. UpToDate and guideline summaries are cited to support that serum assays and imaging remain imperfect substitutes for histology.
The policy includes explicit constraints to limit overuse and duplicate testing: performance of transient elastography, FibroTest‑ActiTest/HCV‑FibroSure, MRE, or ELF more than twice per year is considered not medically necessary, and repeating any of these noninvasive fibrosis tests within 6 months following a liver biopsy or another listed fibrosis test is considered not medically necessary and may be denied. It also notes contexts in which specific tests are unreliable or not indicated (for example, transient elastography is unreliable during episodes of acute liver injury and noninvasive tests have no role in diagnosing glycogenic hepatopathy in place of biopsy).
The document highlights evidence limitations for emerging technologies: mpMRI/LiverMultiScan and other quantitative MRI indices have limited multicenter and cross‑vendor validation and therefore are considered investigational pending broader validation; published single‑center studies require further prospective, multi‑site validation before routine clinical replacement of biopsy. Similarly, the policy cites studies showing lack of correlation (e.g., serum ACE with fibrosis stage) or inadequate sensitivity/specificity (e.g., CK‑18 for NASH) to justify investigational determinations for several serum markers.
Finally, the policy underscores provider documentation expectations and authorization considerations: when reporting elastography include the median kPa and number of valid measurements, document numeric serum panel scores when used for management, and submit claims with the matching diagnosis codes. The policy does not specify a uniform prior authorization requirement in the excerpt; providers are directed to the Clinical Policy Bulletin and plan provisions for any plan‑specific prior authorization rules.